Merck, 356310-1GM, Glyburide

General description
A sulfonylurea that selectively blocks ATP-sensitive K⁺ channels. Reduced K⁺ conductance causes membrane depolarization and influx of Ca²⁺ through voltage sensitive Ca²⁺ channels. Blocks vascular smooth muscle relaxation produced by KATP channel openers. Inhibits the vasorelaxing effects of nitric oxide.
Antidiabetic sulfonylurea that selectively blocks ATP-sensitive K⁺ channels. Reduced K⁺ conductance causes membrane depolarization and influx of Ca²⁺ through voltage sensitive Ca²⁺ channels. Blocks vascular smooth muscle relaxation produced by KATP channel openers. High-affinity binding sites are widely distributed and have been identified in the cardiovascular system, the central nervous system, and pancreatic β-cells. In cultured cells, glyburide enhances insulin action and stimulates the synthesis of glucose transporters. Displays large potency difference in action on pancreatic tissue (IC₅₀ in nM range) and vascular tissue (IC₅₀ in µM range).
Biochem/physiol Actions
Cell permeable: no
Primary Target
ATP-sensitive K+ channels
Product does not compete with ATP.
Reversible: no
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Holzmann, S., et al. 1992. Eur. J. Pharmacol.215, 1.
Rabuazzo, A.M., et al. 1992. Endocrinology131, 1815.
Miller, J.A., et al. 1991. J. Pharmacol. Exp. Ther.256, 358.
Jacobs, D.R., et al. 1989. Diabetes 38, 205.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)